| Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights |
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 – – Tourmaline expects to provide further details on the clinical development plan for pacibekitug within cardiovascular inflammation in conjunction with reporting TRANQUILITY topline data – – Cash, cash equivalents, and investments of $275.3 million as of March 31, 2025 provide expected cash runway into the second half of 2027 – NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the first quarter of 2025 and outlined recent business highlights. “We continue to see growing evidence and enthusiasm for the potential of addressing IL-6-driven cardiovascular inflammation through our discussions with cardiovascular disease experts, attendance at major medical conferences, and review of constantly emerging scientific literature,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. |
globenewswire.com |
2025-05-02 11:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights |
– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the second quarter of 2025 – – Cardiovascular Scientific Advisory Board strengthened with recent appointments of Drs. Deepak L. Bhatt, Dipender Gill, Paul M. |
globenewswire.com |
2025-03-13 09:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 |
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: |
globenewswire.com |
2025-03-03 09:15:00 |
Czytaj oryginał (ang.) |
| Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker |
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, has joined Tourmaline's Cardiovascular Scientific Advisory Board (CV SAB). |
globenewswire.com |
2025-01-10 09:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day |
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD, PhD join Cardiovascular Scientific Advisory Board – – Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven cardiovascular disease – NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today is hosting its Investor Day, beginning at 10 a.m. |
globenewswire.com |
2024-12-10 10:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 |
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a virtual Investor Day on December 10, 2024, beginning at 10 a.m. ET. The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular medicine specialist serving as Executive Director of CPC Clinical Research and Professor of Medicine and William R. |
globenewswire.com |
2024-11-14 09:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
– On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024 – – Cash, cash equivalents and investments of $314.4 million as of September 30, 2024, providing cash runway into 2027 – NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the third quarter of 2024 and outlined recent business highlights. “We are proud of the continued momentum building at Tourmaline, highlighted by the formation of our Cardiovascular Scientific Advisory Board last month,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. |
globenewswire.com |
2024-11-07 09:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio to Present at Upcoming Investor Conferences |
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences: Truist Securities BioPharma Symposium, New York Panel: Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle Illnesses Thursday, November 7, 2024 at 2:35 pm ET Guggenheim Securities Healthcare Innovation Conference, Boston Fireside ChatTuesday, November 12, 2024 at 1:30 pm ET Live webcasts and replays, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com . For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X. |
globenewswire.com |
2024-10-31 09:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 |
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November |
globenewswire.com |
2024-10-15 11:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting |
Tourmaline Bio's Pacibekitug shows promise in treating thyroid eye disease, with pivotal phase 2b data expected in 2025 and a phase 3 study starting in 2024. The 7 major thyroid eye disease markets are expected to reach $4.13 billion by 2034. The company is also exploring Pacibekitug for atherosclerotic cardiovascular disease, with phase 2 TRANQUILITY study results anticipated in the first half of 2025. |
seekingalpha.com |
2024-10-13 14:29:55 |
Czytaj oryginał (ang.) |
| Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress |
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it expects to present two posters at the upcoming 19th Annual Cardiometabolic Health Congress (CMHC), taking place October 17-19, 2024, in Boston, MA. These posters highlight Tourmaline's ongoing commitment to further characterizing inflammatory cardiovascular risk, as well as potential therapeutic mechanisms of IL-6 inhibition. |
globenewswire.com |
2024-10-11 11:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board |
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the treatment of cardiovascular diseases – NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the formation of its Cardiovascular Scientific Advisory Board (CV SAB). The CV SAB is expected to provide strategic guidance and expertise as Tourmaline advances its pacibekitug cardiovascular diseases program, including the TRANQUILITY Phase 2 clinical trial that commenced earlier this year and for which Tourmaline continues to expect topline data in the first half of 2025. |
globenewswire.com |
2024-10-08 11:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio to Present at Upcoming Investor Conferences |
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conferences: H.C. |
globenewswire.com |
2024-09-03 11:45:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights |
– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye Disease (TED) in the second half of 2024 – – Added to the Russell 2000® Index and the broad-market Russell 3000® Index in June 2024 – – Cash, cash equivalents and investments of $334.4 million as of June 30, 2024, providing cash runway into 2027 – NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the second quarter of 2024 and outlined recent business highlights. “The second quarter of 2024 was another period of strong execution by Tourmaline, including the dosing of the first patient in the Phase 2 TRANQUILITY trial. |
globenewswire.com |
2024-08-08 11:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024 |
Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP — Dosing regimens are informed by six previous Phase 1 and Phase 2 clinical studies in healthy volunteers and patients with inflammatory autoimmune disorders, as well as PK/PD modeling — Topline data is expected first half of 2025 — Data from Phase 2 TRANQUILITY trial have the potential to advance TOUR006 toward Phase 3 readiness for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases. NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today presented a poster at the American Society of Preventive Cardiology (ASPC) Congress in Salt Lake City, Utah, detailing the rationale and design of the company's TRANQUILITY Phase 2 study examining the potential of its lead candidate, TOUR006, to reduce high-sensitivity C-reactive protein (hs-CRP), a key biomarker of residual inflammatory cardiovascular risk, in patients with chronic kidney disease (CKD) and elevated hs-CRP. |
globenewswire.com |
2024-08-02 20:30:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer |
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Mr. Robinson most recently held the role of Vice President, Finance and Controller at Tourmaline, in addition to serving as Tourmaline's Interim Chief Financial Officer and Treasurer since October 2023. |
globenewswire.com |
2024-06-27 12:05:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio to Present at the Jefferies Global Healthcare Conference |
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conference: Jefferies Global Healthcare Conference, New York Corporate PresentationThursday, June 6, 2024 at 2:30 pm ET A live webcast and replay will be posted under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at https://ir.tourmalinebio.com. About Tourmaline Bio, Inc. Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. |
globenewswire.com |
2024-05-23 11:10:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial |
– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated in the first half of 2025 with potential to advance TOUR006 toward Phase 3 readiness for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases – – TRANQUILITY trial intended to provide evidence of TOUR006's best-in-class potential for ASCVD, including the potential for quarterly subcutaneous dosing – NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that the first patient has been dosed in its Phase 2 TRANQUILITY trial, marking the initiation of its clinical development program for TOUR006, a long-acting, fully human, anti-IL-6 monoclonal antibody, for the treatment of atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases. TRANQUILITY is a randomized, double-blind, placebo-controlled trial enrolling patients with inflammatory risk, manifesting as elevated high-sensitivity C-reactive protein (hs-CRP) at baseline, and chronic kidney disease (CKD). |
globenewswire.com |
2024-05-16 11:00:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights |
– Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) – – Expanded Thyroid Eye Disease (TED) clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Completed underwritten follow-on public offering in January 2024, raising gross proceeds of $172.5 million – – Ended the quarter with $350.3 million of cash, cash equivalents and investments, providing cash runway into 2027 – NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced its financial results for the first quarter ended March 31, 2024 and outlined recent business highlights. “During the first quarter of 2024, we continued to execute on our two strategic paths for TOUR006, including the initiation of our Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein (hs-CRP) and chronic kidney disease (CKD). |
globenewswire.com |
2024-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights |
– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – |
globenewswire.com |
2024-03-19 09:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Tourmaline Bio, Inc. (TRML) Should Keep going |
Tourmaline Bio, Inc. (TRML) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2024-03-15 11:51:11 |
Czytaj oryginał (ang.) |
| Tourmaline Bio to Present at Upcoming Investor Conferences |
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will participate in the following investor conferences in March. |
globenewswire.com |
2024-02-27 09:30:00 |
Czytaj oryginał (ang.) |
| What Makes Tourmaline Bio, Inc. (TRML) a Good Fit for 'Trend Investing' |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Tourmaline Bio, Inc. (TRML) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-02-08 11:51:11 |
Czytaj oryginał (ang.) |
| Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference |
NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will present at the in the following investor conference: |
globenewswire.com |
2024-02-01 10:00:00 |
Czytaj oryginał (ang.) |